| First Author | Kohler R | Year | 2023 |
| Journal | Bone | Volume | 179 |
| Pages | 116970 | PubMed ID | 37977416 |
| Mgi Jnum | J:342884 | Mgi Id | MGI:7561233 |
| Doi | 10.1016/j.bone.2023.116970 | Citation | Kohler R, et al. (2023) Effects of novel raloxifene analogs alone or in combination with mechanical loading in the Col1a2(G610c/+) murine model of osteogenesis imperfecta. Bone 179:116970 |
| abstractText | Osteogenesis imperfecta (OI) is a hereditary bone disease in which gene mutations affect collagen formation, leading to a weak, brittle bone phenotype that can cause severe skeletal deformity and increased fracture risk. OI interventions typically repurpose osteoporosis medications to increase bone mass, but this approach does not address compromised tissue-level material properties. Raloxifene (RAL) is a mild anti-resorptive used to treat osteoporosis that has also been shown to increase bone strength by a-cellularly increasing bone bound water content, but RAL cannot be administered to children due to its hormonal activity. The goal of this study was to test a RAL analog with no estrogen receptor (ER) signaling but maintained ability to reduce fracture risk. The best performing analog from a previous analog characterization project, named RAL-ADM, was tested in an in vivo study. Female wildtype (WT) and Col1a2(G610C/+) (G610C) mice were randomly assigned to treated or untreated groups, for a total of 4 groups (n = 15). Starting at 10 weeks of age, all mice underwent compressive tibial loading 3x/week to induce an anabolic bone formation response in conjunction with RAL-ADM treatment (0.5 mg/kg; 5x/week) for 6 weeks. Tibiae were scanned via microcomputed tomography then tested to failure in four-point bending. RAL-ADM had reduced ER affinity, and increased post-yield properties, but did not improve bone strength in OI animals, suggesting some properties can be improved by RAL analogs but further development is needed to create an analog with decidedly positive impacts to OI bone. |
